Mark Prygocki

chief executive officer & board member

Over 25 years in the pharmaceutical industry specializing in business development, corporate strategy and operational efficiency.  Mr. Prygocki was President of Medicis Pharmaceutical Corporation.  He was employed with Medicis from 1991 until its acquisition in 2012. Currently acting as a board member and consultant to the pharmaceutical industry and operating several privately-held retail companies.

Director, Chairman, Audit Committee and Member, Nominating and Compensation Committees of the Board of Directors of Verrica Pharmaceuticals. May 2018-Present. Director, Chairman, Audit Committee of the Board of Directors, Clarus Therapeutic, Inc.  July 2014-Present. Prior to joining Medicis; employed by Citigroup, an investment banking firm, in the regulatory reporting division, and by Ernst & Young, LLP, in the auditing department.  Served for greater than 15 years on the Board of Whispering Hope Ranch Foundation, a non-profit organization that assists children with special needs.

Jonah Shacknai

Chairman of the Board

Jonah Shacknai co-founded Illustris Pharmaceuticals. In addition, he serves as Executive Chairman of DermaForce Partners, an aesthetics technology firm that develops and globally commercializes novel cosmetic and OTC products in multiple channels, including the new doctor-dispensed skincare brand SkinBetter Science. Prior to co-founding Illustris and DermaForce, Mr. Shacknai was the founder, Chairman, and Chief Executive Officer of Medicis Pharmaceuticals Corporation. Mr. Shacknai has an extremely well diversified public service, law and corporate background, with vast experience and expertise in the pharmaceutical and healthcare industries. 

Learn more



Dr. Waugh is the Founder, Chief Scientific Officer, Medical Director, and a member of the board of directors of Illustris Pharmaceuticals, Inc.  He has over 26 years of experience in applied cross-disciplinary research. He is the Co-Founder of Revance Therapeutics. He trained with pioneering leaders in molecular medicine and chemistry, has received numerous awards, and has authored over 40 research manuscripts and publications.

Dr. Waugh served as a Senior Scientist at Stanford University School of Medicine from 2001 to 2004, where he pioneered in vivo tissue engineering applications. Dr. Waugh has also served as an advisor in the medical device and pharmaceutical industries as well as a reviewer for number of prominent scientific and medical journals. 


Board Member

Dr. Tan currently practices in Singapore, having graduated from medical school in 1971. He has postgraduate qualifications in Dermatology and Venereology, and Cosmetic Science, and an MBA from the Maastricht Business School.  He was a founding member of Derma-Rx and The DRx Clinic before founding the IDS Clinic and launching the IDS range of skincare products.  He is a Fellow of the American Academy of Dermatology (FAAD) and has published, and has been a reviewer, in international dermatology and cosmetic dermatology journals.

As Head of Investment Banking at Triad Securities Corporation, Mr. Hirschberg is focused on M&A and Strategic life science transactions within the specialty pharmaceutical sector. Prior to joining Triad Securities, Mr. Hirschberg served as Managing Director at Roberts Mitani, LLC from July 2011 through December 2013. From May 1984 through June 2011, Mr. Hirschberg served as President of Corporate Development Specialists Inc., a firm which provided advisory services to pharmaceutical, device, consumer and biomedical companies.

Mr. Hirschberg received a B.A. from Colgate University, a Masters in Accounting from NYU Stern School of Business, and an MBA from University of Chicago Graduate School of Business.

Andrew HIrschberg

Board Member


Board Member

Seth Rodner is the co-Founder and President of DermaForce Partners, a leading aesthetic technology company focused on research, development and multi-channel worldwide commercialization of scientific innovation in prestige clinical skincare, anti-aging and beauty.  Mr. Rodner previously served as a federal prosecutor with the U.S. Department of Justice in Washington, D.C.; an equity partner in a prominent Florida law firm, where his nationwide practice focused on government investigations and board counseling in life sciences and other regulated industries; and most recently as Executive Vice President, Chief Legal Officer and Corporate Secretary of Medicis Pharmaceutical Corporation.  Mr. Rodner earned his B.A. from Amherst College in 1991 and J.D. from Duke University School of Law in 1994.